[Current therapy for multiple myeloma].
Swieboda-Sadlej
Anna
A
Katedra i Klinika Hematologii, Onkologii i Chorób Wewnetrznych Akademii Medycznej w Warszawie. asadlej@amwaw.edu.pl
D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib